TNF revisited: Osteoprotegerin and TNF-related molecules in heart failure

Current Heart Failure Reports

Volumn 9, Issue 2, 2012, Pages 92-100

  Ueland, Thor ^a   Yndestad, Arne ^b   Dahl, Christen P ^b   Gullestad, Lars ^b   Aukrust, Pål ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Biomarker; Cardiac hypertrophy; Extracellular matrix remodeling; Heart failure; Inflammation; OPG; Osteoprotegerin; Pathophysiology; TNF. Tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; BIOLOGICAL MARKER; LIGAND; TUMOR NECROSIS FACTOR ALPHA;

ADVERSE OUTCOME; APOPTOSIS; ARTICLE; DISEASE MARKER; EXTRACELLULAR MATRIX; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CELL; INFLAMMATION; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BLOOD; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

APOPTOSIS; BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; LIGANDS; OSTEOPROTEGERIN; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864881461     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0088-6     Document Type: Article

References (86)

1. Jessup M, Brozena S. Heart failure. N Engl JMed. 2003;348:2007-18.
2. Mann DL, Deswal A, Bozkurt B, Torre-Amione G. New therapeutics for chronic heart failure. Annu Rev Med. 2002;53:59-74. (Pubitemid 34177871)
3. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97:1136-43. (Pubitemid 28152886)
4. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-82. (Pubitemid 29066497)
5. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41. (Pubitemid 20225044)
6. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-98. (Pubitemid 35416635)
7. Ware CF. The TNF superfamily. Cytokine Growth Factor Rev. 2003;14:181-4.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-56. (Pubitemid 41070815)
9. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193-209. (Pubitemid 36693141)
10. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest. 2002;109:373-81. (Pubitemid 34141811)
11. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111-3. (Pubitemid 27161256)
12. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factoralpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-11.
13. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/ RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-8. (Pubitemid 40696134)
14. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, et al. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest. 1999;115:1170-4. (Pubitemid 29193693)
15. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAFmediated signal transduction. J Cell Sci. 2002;115:679-88. (Pubitemid 34196328)
16. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66:1403-8. (Pubitemid 38373326)
17. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-8. (Pubitemid 38610351)
18. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med. 2010;207:391-404.
19. Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol. 1997;29:1214-20. (Pubitemid 27201937)
20. Yamaguchi S, Yamaoka M, Okuyama M et al.: Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol. 1999;83:1500-1503, A8. (Pubitemid 29228352)
21. Yndestad A, Damas JK, Geir EH, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res. 2002;54:175-82.
22. Schoppet M, Ruppert V, Hofbauer LC, et al. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun. 2005;338:1745-50. (Pubitemid 41643085)
23. Ueland T, Aukrust P, Yndestad A, et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J. 2005;26:1101-7. (Pubitemid 40839911)
24. Jeremias I, Kupatt C, Martin-Villalba A, et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 2000;102:915-20.
25. Madry C, Laabi Y, Callebaut I, et al. The characterization of murine BCMA gene defines it as a newmember of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10:1693-702. (Pubitemid 28502383)
26. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 1997;272:14272-6. (Pubitemid 27232840)
27. MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;272:25417-20. (Pubitemid 27438841)
28. Pan G, Ni J, Yu G, et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 1998;424:41-5. (Pubitemid 28130348)
29. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-8. (Pubitemid 27366732)
30. Wilson EM, Diwan A, Spinale FG, Mann DL. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004;37:801-11. (Pubitemid 39222072)
31. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-7. (Pubitemid 32200174)
32. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40. (Pubitemid 36793081)
33. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602. (Pubitemid 38451714)
34. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-29.
35. Darnay BG, Aggarwal BB. Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis. 1999;58 Suppl 1:I2-I13.
36. Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol Med. 2003;9:177-82. (Pubitemid 36626707)
37. Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol. 2005;38:47-62. (Pubitemid 40038651)
38. Linke A, Recchia F, Zhang X, Hintze TH. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev. 2003;8:87-97. (Pubitemid 36342292)
39. Yndestad A, Holm AM, Muller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res. 2003;60:141-6. (Pubitemid 38373485)
40. Varda-Bloom N, Leor J, Ohad DG, et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol. 2000;32:2141-9. (Pubitemid 32039766)
41. Nitobe J, Yamaguchi S, Okuyama M, et al. Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res. 2003;57:119-28. (Pubitemid 36009443)
42. Yaniv G, Shilkrut M, Lotan R, et al. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc Res. 2002;54:611-23. (Pubitemid 34595420)
43. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003;14:337-48. (Pubitemid 36693152)
44. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 2002;13:199-207. (Pubitemid 34693174)
45. Hamid T, Gu Y, Ortines RV, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386-97. This experimental study illustrates the complexity of the interplay between TNF-related molecules in HF by showing disparate and opposing effects by TNFR1 and TNFR2 on myocardial remodeling, hypertrophy, NF-κB activation, inflammation, and apoptosis.
46. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-31. (Pubitemid 32762683)
47. Nelson DP, Setser E, Hall DG, et al. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000;105:1199-208. (Pubitemid 30266072)
48. Li YY, Kadokami T, Wang P, et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 2002;282:H983-9. (Pubitemid 34654937)
49. Lee WH, Kim SH, Lee Y, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol. 2001;21:2004-10. (Pubitemid 34219754)
50. Mach F, Schonbeck U, Fabunmi RP, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40Ldependent mechanism: implications for tubule formation. Am J Pathol. 1999;154:229-38. (Pubitemid 29031630)
51. Yurovsky VV. Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol. 2003;28:225-31. (Pubitemid 36169652)
52. Voloshenyuk TG, Hart AD, Khoutorova E, Gardner JD. TNFalpha increases cardiac fibroblast lysyl oxidase expression through TGF-beta and PI3Kinase signaling pathways. Biochem Biophys Res Commun. 2011;413:370-5. This study illustrates the complex role of TNF-related molecules in ECM remodeling, promoting both matrix degradation and enhanced collagen synthesis partly depending on co-stimuli and concentration of TNF-related molecule.
53. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-6. (Pubitemid 39473280)
54. Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol. 2008;84:213-7.
55. Ueland T, Aukrust P, Dahl CP, et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med. 2011;270:452-60.
56. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251-63. (Pubitemid 36693145)
57. Feng W, Li W, Liu W, et al. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenolinduced heart failure. Exp Mol Pathol. 2009;87:212-8.
58. Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-63. (Pubitemid 43732163)
59. Halapas A, Zacharoulis A, Theocharis S, et al. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med. 2008;46:510-6. (Pubitemid 351820350)
60. Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30:789-96. This study describes discrepant effects of soluble TNF-related markers of apoptosis on the prognosis of advanced HF and indicates that sTRAIL could be of interest as a therapeutic agent. It also illustrates the importance of fully understanding pathophysiological processes before selecting specific pathways as therapeutic target.
61. Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/ TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 2010;210:274-7.
62. Corallini F, Secchiero P, Beltrami AP, et al. TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. Cell Mol Life Sci. 2010;67:1307-14.
63. Roysland R, Masson S, Omland T, et al. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J. 2010;160:286-93.
64. Ueland T, Dahl CP, Kjekshus J, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail. 2011;4:145-52.
65. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16:348-60. (Pubitemid 32105416)
66. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-87.
67. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
68. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-52. (Pubitemid 46328287)
69. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-7.
70. Orus J, Roig E, Perez-Villa F, et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant. 2000;19:419-25. (Pubitemid 30249079)
71. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-9. (Pubitemid 32373007)
72. Miettinen KH, Lassus J, Harjola VP, et al. Prognostic role of proand anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail. 2008;10:396-403.
73. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factoralpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation. 2005;111:863-70. (Pubitemid 40279887)
74. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, et al. Tumour Necrosis Factor alpha and Troponin Tas predictors of poor prognosis in patients with stable heart failure. Clin Invest Med. 2005;28:23-9. (Pubitemid 40283422)
75. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002;39:1145-50. (Pubitemid 34267417)
76. Petrovsky N, Harrison LC. The chronobiology of human cytokine production. Int Rev Immunol. 1998;16:635-49. (Pubitemid 28286188)
77. Chorianopoulos E, Rosenberg M, Zugck C, et al. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail. 2009;11:1050-6.
78. Richter B, Rychli K, Hohensinner PJ, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis. 2010;213:545-8.
79. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479-86.
80. Ueland T, Kjekshus J, Froland SS, et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol. 2005;46:2018-21. (Pubitemid 41713585)
81. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008;159:603-8.
82. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-8. (Pubitemid 46809385)
83. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-33. (Pubitemid 351193104)
84. Jellema A, Plat J, Mensink RP. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest. 2004;34:766-73. (Pubitemid 39524302)
85. Haack M, Pollmacher T, Mullington JM. Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun. 2004;18:361-7. (Pubitemid 38648833)
86. Ueland T, Aukrust P, Damas JK, et al. The tumor necrosis factor superfamily in heart failure. Future Cardiol. 2006;2:101-11.